Organon v. Mylan Pharmaceuticals

Analysis Group was retained by counsel for Organon, Inc., in connection with antitrust claims surrounding the antidepressant Remeron. Generic competitors, direct and indirect purchasers, and third-party payers alleged that anticompetitive behavior prevented the timely introduction of generic Mirtazapine. Analysis Group Chairman Bruce Stangle evaluated plaintiffs’ damages claims, including attention to the trends in brand and generic prices as well as shares of compound sales pre- and post-generic entry. Professor Janusz Ordover of New York University analyzed market definition with support from our team. This included examination of switching patterns in response to price and non-price drivers based on granular patient-level data, and the impact of discounts and rebates on formulary positioning. Our team, which included Managing Principal Paul Greenberg, Principal George Kosicki, and Vice Presidents Tamar Sisitsky, David Mishol, and Richard Mortimer, also provided extensive consulting support to counsel in settlement negotiations.